Modeling analysis ranks tirzepatide above semaglutide and orforglipron

The wire

1. 01An Omics paper combined trial evidence, molecular descriptors and multi-criteria decision analysis, ranking tirzepatide highest under balanced, efficacy- and safety-weighted models.
2. 02Orforglipron, the first oral non-peptide GLP-1 agonist to finish phase 3, ranked first only under an accessibility-weighted model driven by oral dosing and manufacturing scale.
3. 03This is a computational re-analysis, not new clinical data; the authors note the balanced model was fragile under Monte Carlo sensitivity testing.

From the source

Oral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide

Omics : a journal of integrative biology · 2026 Oct 20 · Sahu L, Nayak L, Tripathy A et al.